Obstructive lung disease
Drug research and approvals for obstructive lung disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 812 studies of obstructive lung disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 812
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk TestNCT07938086 · Not applicable · Aether Tech S.L. · starts Apr 15, 2026
- The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and…NCT07934654 · Not reported · Bielefeld University · starts Mar 1, 2024
- Cardiopulmonary Exercise Active Health Cohort StudyNCT07935187 · Not reported · Peking University Third Hospital · starts May 11, 2026
- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants…NCT07915791 · Phase 2 · GlaxoSmithKline · starts Oct 29, 2026
- Reducing Exposure With Air Cleaners and TechnologyNCT07914010 · Not applicable · University of California, Berkeley · starts Nov 17, 2026
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High…NCT07908381 · Phase 2 / Phase 3 · Enanta Pharmaceuticals, Inc · starts Oct 19, 2026
- Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and Management of…NCT07910409 · Not reported · Beijing Chao Yang Hospital · starts Apr 1, 2026
- Multimodal Assessment of Neuromuscular Electrical Stimulation (NMES) Effects on Respiratory and Peripheral Muscles in…NCT07910006 · Not applicable · Universitas Padjadjaran · starts Nov 1, 2026
Approved 24 of 52
- FormoterolBeta-2 adrenergic receptor agonist
- AlbuterolBeta-2 adrenergic receptor agonist
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- OmalizumabIg epsilon chain C region inhibitor
- ReslizumabInterleukin-5 inhibitor
- SalmeterolBeta-2 adrenergic receptor agonist
- TerbutalineBeta-2 adrenergic receptor agonist
- Fenspiride
- MetaproterenolBeta-2 adrenergic receptor agonist
- FenoterolBeta-2 adrenergic receptor agonist
- BudesonideGlucocorticoid receptor agonist
- AclidiniumMuscarinic acetylcholine receptor M3 antagonist
- TiotropiumMuscarinic acetylcholine receptor M3 antagonist
- IpratropiumMuscarinic acetylcholine receptor M3 antagonist
- GlycopyrroniumMuscarinic acetylcholine receptor M3 antagonist
- ZafirlukastCysteinyl leukotriene receptor 1 antagonist
- FlunisolideGlucocorticoid receptor agonist
- Beclomethasone dipropionateGlucocorticoid receptor agonist
- TriamcinoloneGlucocorticoid receptor agonist
- Fluticasone furoateGlucocorticoid receptor agonist
- Mometasone furoateGlucocorticoid receptor agonist
- CiclesonideGlucocorticoid receptor agonist
- Fluticasone propionateGlucocorticoid receptor agonist
- AmlexanoxPhosphodiesterase 4 inhibitor
Phase 3 4
- BambuterolBeta-2 adrenergic receptor agonist
- ProcaterolBeta-2 adrenergic receptor agonist
- Theobromine
- Doxofylline
Phase 2 10
- DexamethasoneGlucocorticoid receptor agonist
- Sodium iodide
- AZD3199Beta-2 adrenergic receptor agonist
- Tretoquinol
- Etamiphyllin
- Eprozinol
- Metaproterenol polistirex
- Hexoprenaline
- Bamifylline
- Carbuterol
How its trials ended
2,861 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 729 whose ending is known, 56% met their primary endpoint, 10% missed it and 34% stopped early.
- Completed, result not reported1,30145%
- Status unknown42915%
- Met its primary endpoint40914%
- Ongoing40214%
- Stopped: other or unclear1485%
- Missed its primary endpoint743%
- Stopped: enrollment or feasibility572%
- Stopped: sponsor or business decision221%
- Stopped: funding10<1%
- Stopped: lack of efficacy8<1%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA